In pre-clinical studies, everolimus combined with anti-PD-L1 was more effective in decreasing tumor burden compared to individual treatment in a mouse model of renal cell carcinoma due to upregulation of PD-L1 in the tumor cells resulting in increased tumor infiltrating CD8+ lymphocytes and tumor regression [345]. This evidence concerns the gene CD274 and neoplasm.